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EVALUATION OF HOMOCYSTEINE AND FOLIC 
ACID LEVELS IN PREGNANCY LOSS 
 
ABSTRACT 
STUDY PERIOD 
The period of study was from JANUARY 2015 – DECEMBER 2015 
STUDY DESIGN 
Observational study 
METHODOLOGY 
• Study population includes patients  with pregnancy loss within 13 weeks 
of menstrual age 
• To measure fasting homo cysteine & folic acid levels 
 
INCLUSION CRITERIA 
CASES –  
• In my study 100 Patients  with pregnancy loss within 13 weeks of 
menstrual age  
CONTROLS –100   controls chosen  
• Patients attending ante natal outpatient department who had at least 
one live child with no history of previous abortions. 
 
 
 
 
 
EXCLUSION CRITERIA 
Patients with  
• Increased serum creatinine 
• Increased serum alanine amino transferase 
• Ectopic pregnancy  
• Molar pregnancy 
• Chronic hyper tension 
• Diabetes mellitus 
• Preexisting liver or renal disorder 
• History of thromboembolism 
• Abruptio placenta 
• Pre term labour 
• Anemia  
• Smoking 
• B12 & folic acid supplementation 
 
All pregnancies to be confirmed by a positive urinary hCG test or 
ultrasound imaging. 
• Fasting Blood sample taken after obtaining consent from the 
Patient 
 
CONCLUSION  INCREASED homocystine and DECREASED folic acid 
level in patients with pregnancy loss & treating patients with FOLIC ACID 
& Multi VIT tablets. In my study out of 100 cases 21 patient where with 
increased homocystine and 41 patients with decreased folic acid level and 
therapeutic dosage of folic acid given. This study shows p value less than 
.001 which is highly significant. 
 Thus I conclude evaluation of homocystine and folic acid levels can be a 
marker for prediction for pregnancy in future. 
• Pedigree analysis of the patients done detail 
KEYWORDS : 
• Homocystine 
• Folic acid  
• Pregnancy Loss 
  
INTRODUCTION 
 Recurrent pregnancy loss affects 1 in 300 and 1 in 100 couples 
 Parenteral chromosomal abnormalities and anti-phospholipid antibody 
syndrome are the undisputed causes of pregnancy loss. 
The pathogenesis of spontaneous abortion involves   interaction 
of several genetic and environmental factors. Increased homocysteine 
concentration leads to neural tube defects (NTD) and also hyper 
homocysteinemia is embryotoxic and lead to decreased fetal viability. 
 Defects in Folate- and vitamin B12-dependent homocysteine 
metabolism are linked with  genetic polymorphism (Henrik Zetterberg 
et al) Transmethylation of methionine leads to formation of 
homocysteine  and  its metabolism depends  primarily on four enzymes 
– methyl tetra hydro folate reductase, cysta thionine beta synthase, 
methionine synthase, acetyl choline transferase and several vitamin 
cofactors.      
Fasting value 15 micro mol/l - cut off value for 
hyperhomocystenemia     HHCh belongs among the congenital 
hypercoagulable states and is a long-known vascular disease risk 
  
factor. HHCh is  responsible for several pregnancy complications  such 
as      
1. Early pregnancy loss 
2. Pre eclampsia 
3. Abruption 
4. Intra uterine death 
5. Still births 
6. Neural tube defects 
7. Growth restriction 
8. Thromboembolic episodes 
 
Anticoagulant treatment –the treatment for thromboembolic 
episodes during pregnancy(Aubard Y etal.,2000) Folates belong to the 
vitamin B group and are involved in a large number of biochemical 
processes, particularly in the metabolism of homocysteine. Any 
research in this field would prove immense help to patients with 
recurrent miscarriage as well help them in preventing future 
complications not only of pregnancy but also in preventing coronary 
artery disease, dementia, osteoporosis, lack of concentration and 
underachievement for which they are more prone. It is shown by 
studies that women with recurrent miscarriage were more likely to 
  
have family history of cardiovascular disease (GCS Smith, AM Wood, 
JP Pell, J Hattie)[2] 
Other causes are: 
o Anatomic 
o Endocrine 
o Thrombotic 
o Immunologic factors. 
 Altered balance between pro-thrombotic and antithrombotic 
factors. 
 Evaluation by detailed family history and patient history, 
focused mainly on endocrine and anatomical abnormalities.  
 Early pregnancy loss monitored by a)USG b) beta- HCG c) 
Karyotype analysis. 
Treatment of Recurrent pregnancy loss:   
 Correction of anatomic abnormalities 
 Correcting preexisting endocrine disorders 
 Antiphospholipid antibody syndrome and thrombophilic 
disorders to be treated. 
 Incidence of Pregnancy loss 15% - clinically recognized before 
20 weeks from last menstrual period. 
  
Risk of subsequent pregnancy loss in previous history of 
recurrent pregnancy losses 24% after 2 losses, 30% after 3 losses, 40%  
– 50% after 4 losses  70% of human conceptions fail to achieve 
viability,  50% are lost before the first missed menstrual period. 
 
 
 
 
 
 
 
 
 
 
 
 
  
AIMS & OBJECTIVES 
 
• To evaluate  homocysteine & folic acid levels in 
pregnancy loss within 13 weeks of menstrual age. 
• 100 cases and 100 controls in selection criteria 
• Treating patients with folic acid and multi vitamin tablets 
with elevated homocysteine levels and decreased folic 
acid levels 
 
 
 
 
 
 
 
 
  
REVIEW OF LITERATURE 
The term miscarriage is used to define a pregnancy that fails to 
progress , resulting in death and expulsion of a embryo ≤ 500 gms equal to 20 
weeks of pregnancy. Spontaneous miscarriage is the commonest 
complication of pregnancy. It occurs in up to 20% of clinical pregnancies( 
Poulose et al). 
 
 
  
 
 
 
 
  
 AGE RELATED MISCARRIAGES 
 
 
 
 
 
  
 
ETIOLOGIES FOR RECURRENT SPONTANEOUS ABORTION 
ETIOLOGY  INCIDENCE 
A. Genetic factors 3.5% - 5% 
 1. Chromosomal 
 2. Single gene defects 
 3. Multifactorial  
B. Anatomic factors 12% - 16% 
 1. Congenital 
     a. incomplete mullerian fusion or septum resorption 
     b. Diethylstilbestrol exposure 
    c. uterine artery manomalies 
 d. cervical incompetence 
 
  
 2. Acquired 
  a. cervical incompetence 
 b. synechiae 
 c. leiomyomas 
 d. adenomyosis 
C. Endocrine factors 17% - 20% 
1. luteal phase insufficiency 
2. Polycystic ovarian syndrome, including insulin resistance and 
 hyperandrogenism 
3. Other androgen disorders 
4. Diabetes mellitus 
5. Thyroid disorders 
6. Prolactin disorders 
 
  
D. Infectious factors 0.5% - 5% 
  1. Bacteris 
  2. Viruses 
  3. Parasites 
  4. Zoonotic 
  5. Fungal 
E. Immunologic factors 20% - 50% 
  1. Cellular mechanisms 
 a. Suppressor cell or factor deficiency 
  b. Alterations in major histocompatibilityantigen expression 
  c. Alterations in cellular immune regulation 
1. TH1 immune responses to reproductive antigens (embryo or 
 trophoblast) 
2. Th2 cytokine or growth factor deficiency 
  
3.  Hormonal – progesterone, estrogen, prolactin, androgen 
alterations 
4. Tryptophan metabolism  
2. Humoral mechanisms 
 a. Antiphospholipid antibodies 
 b. Antithyroid antibodies 
 c. Antisperm antibodies 
 d. Antitrophoblast antibodies 
 e. Blocking antibody deficiency 
F. Thrombotic factors incidence 
1. Heritable thrombophilias 
a) Single gene defects (fVL, MTHFR, factor deficiencies) 
b) Antibody mediated thromboses ( APS, anti – β2G1) 
Most are included among other categories (e.g., immune, genetic) 
  
 
Other factors  10% 
1. Altered uterine receptivity (integrins, adhesion molecules) 
2. Environmental  
a) Toxins 
b) Illicit drugs 
i. Cigarettes and caffeine 
1. Placental abnormalities (circumvallate, marginate) 
2. Maternal medical illnesses ( cardiac, renal hematologic) 
3. Male factors 
4. Exercise 
5. Dyssynchronous fertilization. 
 
  
GENETIC FACTORS: The most common contributing to recurrent 
abortion are balanced translocations. 
 
  
 
 
  
 Depending on the nature of the translocations gametes produced by the 
translocations carrier will be normal balanced or unbalanced for the 
translocated DNA. 
         
            
 Among the possible chromosomal monosomies, X chromosome 
permits viable offspring. Compared with monosomies, chromosomal 
trisomies – 13, 18,21 appear to be better tolerated. Mosaicism may be 
implicated with these abnormalities.. Other structural chromosomal 
anomalies, such as inversions and insertions, may also contribute to 
recurrent abortions.  
 Evaluation made by use of parental karyotyping a screening modality 
for recurrent pregnancy loss. 
 
 
 
Fertilisation of a 
chromosomally  
Normal gamete 
Embryo 
Balanced 
Normal 
Unbalanced 
  
ANATOMIC ABNORMALITIES 
 Anatomic abnormalities of both the uterine cervix and the uterine 
body have been associated with recurrent pregnancy loss. 
 
CAUSES     
  
Congenital causes                                                                                                                       
     -incomplete mullerian duct fusion,        
                          -incomplete septum resorption,        
     -uterine cervical anomalies.       
     -Prenatal exposure to diethyl stilbestrol  
     -presence of intrauterine septum  
Acquired causes 
 -Intrauterine adhesions 
  -Uterine fibroids 
   -Endometrial polyps 
 
 
1. CONGENITAL 
2.ACQUIRED 
  
ENDOCRINE ABNORMILITIES 
 
 Endocrine abnormalities mediate their effect during the follicular 
phasee of the cycle in which conception occurs, or even earlier. Beginning 
with ovulation and lasting until approximately 7 to 9 weeks of gestation, 
maintenance of early pregnancy depends on the production of progesterone 
by the corpus luteum. Normal pregnancies are characterized by a luteal-
placental shift at about 7 to 9 weeks gestation during which the developing 
placental trophoblast cells take over progesterone production and maintains 
pregnancy. 
 Pregnancy failures may also occur near the time of the expected luteal 
placental shift if the trophoblast is unable to produce biologically active 
progesterone following  corpus luteum death.   
  Endocrine factors associated with recurrent abortion include luteal 
phase insufficiency, diabetes mellitus, hypersecretion of luteinizing hormone 
(LH), thyroid disease, and, potentially, insulin resistance and polycystic 
ovarian syndrome, hyperprolactinemia and decreased ovarian reserve. 
 Studies report ovarian radiologic evidence of PCOS in as many as 
40% to 80% of recurrent pregnancy loss patients. Many women with PCOS 
have metabolic alteration in glycemic control characterized by insulin 
resistance. This too may be directly or indirectly related to adverse pregnancy 
outcome, and it may explain increases in the rate of spontaneous pregnancy 
  
loss among women with type 2 diabetes mellitus. Women with overt insulin – 
dependent diabetes mellitus (IDDM) appear to exibit a threshold of 
progestational glycemic control above which spontaneous pregnancy loss is 
increased . in fact, hyperglycemia has now been directly linked to embryonic 
damage.            
 In cases of advanced IDDM with accompanying vascular 
complications, compromised blood flow to the uterus may be mechanistically 
involved in subsequent pregnancy loss.  
THROMBOPHILIAS: 
This  heterogenous group of disorders ↑ arterial/ venous thrombosis 
 
 
 
   
 
Thrombophilic states to pregnancy loss 
Heritable thrombophilias : 
    Linked with 
• Activated protein c resistance 
• Associated c factor V mutation 
• Deficiencies in protein C,S 
Abnormal placental vasculatur 
Inappropriate placental thrombiosis 
  
• Mutation in prothrombin 
• Mutation in antithrombin III 
Inherited thrombophlias 
• 15% while have inheritable thrombophilia 
• Factor V leiden mutation 
• Mutation in promoter region of prothrombin gene & 
mutation in gene encoding MTHFR 
More severe thrombophilias such as anti thrombin & protein S 
less common 
IMMUNOLOGICAL FACTORS 
Cellular immunity 
1. Resident endometrial/decidual cells 
a. few B cells 
b. TCRαβ+ and TCRγδ+ cells increase in early pregnancy 
c. NK-like, large granular lymphocytes (decidual NK cells)  
     accumulate at site of implantation 
d. NKT cells and suppressor macrophage 
e. Treg cells 
2. immune cell education and homing 
a. thymic versus extrathymic education 
b.possible in situ education and maintenance 
  
c.integrins/ vascular ligand and mucosal homing 
 
3. Antigen presentation 
a. MHC class II molecules are not expressed in the placenta 
b. classical MHC class I molecules HLA-A and HLA-B are 
not  expressed in the placenta 
c. extravillous cytotrophoblast cells express HLA-C, HLA-E, 
and HLA-G 
4. In situ immunoregulation 
a.TH1/TH2 cytokine microenvironments and dysregulation 
b. Hormonal immunomodulation 
1. Progesterone 
2. Estrogen 
3. Human chorionic gonadotropin (hCG) 
4. prolactin 
5. Androgens 
6. Others 
c. tryptophan metabolism and indolamine 2,3 dioxygenase      
 (IDO) 
d.leukemia inhibiting factor (LIF) 
 
  
Humoral Immunity 
1. Fetal antigens are recognized by the maternal immune system 
and humoral responses are mounted. 
2. Organ nonspecific autoantibodies 
a.Anticardiolipin antibodies 
b.lupus anticoagulant 
c. Anti-β2 glycoprotein-1 (anti-beta2GP-1) antibodies 
d. Antiphosphatidly serine antibodies 
3. Organ specific autoantibodies 
a. Antithyroid antibodies 
b. Antisperm antibodies 
c. Antitrophoblast antibodies 
1. blocking antibodies 
2. HLA sharing 
3. Trophoblast/lymphocyte cross-reactive antibodies 
(TLX)  
  
 HOMOCYSTEINE
demethylation of methionine.
congenital or acquired, is associated with thrombosis and premature 
vascular disease. This condition is also associated with pregnancy loss.
 
 
 
 
 
 
 
 
 
HOMOCYSTIENE 
-A thiol-containing amino acid formed b
 Hyperhomocystinemia, which may be 
y a 
 
 
  
 
The gene for the inherited form is transmitted in an autosomal 
recessive form.  
The most common acquired form is due to deficiency of folic 
acid levels. 
  
In these patients, folic acid replacement helps achieve normal 
homocysteine levels within a few days. 
 
FUNCTIONS:  
• Involved in biosynthesis of  DNA and RNA. 
• Also via cystathionine biosynthase , cysteine is 
synthesized, this step uses pyridoxine as a co- factor. 
• Homocystiene can be recycled to methionine , where N-
5 methyl tetrahydro folate  and co- balamin is used. 
CAUSES OF HYPERHOMOCYSTEINE  
Vitamin deficiency  
-folate  
-B6  
-B12 
• Increasing age 
• Men  
• Tobacco use 
• Decreasing renal functions 
• Enzyme deficiency  
  
 -Cystathionine β synthase 
 -Methionine synthase 
 -5 MTFHR 
 6-Azarudine triacetate 
 
Homozygosity for C 6777 transition MTHFR gene 
    
Thermolabitily of enzyme 
   
 Inhibits Formation of 5 MTHF / (methyl donor) 
 
• Cigarette smoking 
• Hypertension 
• Systemic diseases 
-Chronic renal insufficient 
-Systemic lupus 
-Neoplasm 
-Hypothyroidism 
 
  
HOMOCYSTIENE METABOLISM 
 
HOMOCYSTEINE IN RELATION WITH ATHEROSCLEROSIS 
 HHCY 
 
Increase production & reactive molecules 
(Homocysteine thiolactone) 
 
causes LDL aggregate 
 
  
LDL + macrophage      foam cells 
 
Homocysteine thiolactone molecules 
 
Free radicals 
 
Endothelial damage 
Platelet aggregate 
Activation of coagulation cascade 
Proliferation of vascular smooth cells 
- Forms fibrous term 
- Mucoid matrix 
- Plaque formation 
     Atherosclerosis 
 
 
  
PHYSIOLOGICAL CHANGES IN PREGNANCY DUE TO 
HOMOCYSTEINE 
Homocysteine concentration decreased in pregnancy due to  
 Hemodilution 
 Raised glomerular filtration rate 
 Hormonal changes of pregnancy 
 Increased fetal uptake 
 
RELATION BETWEEN HOMOCYSTEINE AND VITAMIN B12/ 
FOLIC ACID DEFICIENCY  
In vitamin b12 deficiency,  
 Methyl malonic acid            both are increased 
 Homocysteine                                                                                                           
                              [   OR ] 
 Methyl malonic acid level- elevated          
homocysteine level - normal 
In folic acid deficiency, 
 Methyl malonic acid level - normal             
homocysteine level is elevated 
 
  
HOMOCYSTEINE EFFECTS ON PLACENTA 
Placental development requires invasion into deciduas and its vasculature 
requires precise control of haemostasis and fibrinolysis. 
Hormonal & related physiological changes affects 
- clotting cascade 
-fibrinolytic cascade 
-platelet physiology 
 
 
 
 
 
 
 
 Increased  Homocysteine 
 Folate deficiency 
 Homozygous state for MTHFR C677T 
Homozygozity for MTHFR thermolabale variant isolated from 
placental tissue (daly et al, 1988 ]-21 
Maternal folate homocysteine MTHFR defect not only associated with 
serum but also from placenta itself  
Placenta mediated diseases 
- Infarction 
- Abruption 
- Pre eclampsia  
- Recurrent pregnancy loss 
  
EVALUATION AND FOLLOW UP 
History 
• Pattern, trimester, and characteristics of prior pregnancy losses 
• History of subfertility or infertility 
• Menstrual history 
• Prior or current gynecologic or obstetric infections 
• Signs or symptoms of thyroid, prolactin, glucose tolerance and 
hyperandrogenic disorders (including polycystic ovarian 
syndrome) 
• Personal or familial thrombotic history 
• Features associated with the antiphospholoid syndrome 
(thrombosis, false positive test for syphilis) 
• Other autoimmune disorders 
• Medications 
• Environmental exposures, illicit and common drug use 
9particularly caffeine, alcohol, cigarettes, and in utero 
diethylstilbestrol exposure) 
• Genetic relationship between reproductive partners 
• Family history of recurrent spontaneous abortion, of obstetric 
complications, or of any syndrome associated with embryonic or 
fetal losses 
  
• Pervious diagnostic test and treatments, including, if available, 
chromosome testing on products of conception physical 
examination 
a. General ophysical examination with particular attention to: 
a. Obesity 
b. Hirsutism/acanthosis 
c. Thyroid examination 
d. Breast examination/galactorrhea 
e. Pelvic examination 
1. Anatomy 
2. Infection 
3. Trauma 
4. Estrogenization 
5. Masculinization 
LABORATORY 
1. Parental peripheral blood karyotype 
2. Chromosome testing on products of conception 
3. Hysterosalpingography, three-dimensional transvaginal sonography, 
sonohysterography, or office hysteroscopy, followed by 
hestroscopy/laproscopy, if indicated 
  
4. Thyroid stimulating hormone leve, serum prolatin level if indicated 
5. Anticardiolipin antibody levels (lgG and lgM) 
6. Lupus anticoagulant (activated partial thromboplastin time or 
Russell viper venom) 
7. Anti-β2-glycoprotein-1 antibodies (lgG and lgM) 
8. Complete blood count with platelets 
9. Factor V leiden, G20210A prothrombin gene mutation, protein S 
activity, homocysteine level, activated protein c resistance (in white 
patients with suspicious family history)[9] 
10.Protein C activity, antithrombin level if personal or family history 
of venous thromboembolic events  
MANAGEMENT 
ANTITHROMBOTIC THERAPY 
Antithrombotic medications- combined use of low dose asprin (75 to 
80mg/day) and subcutaneous unfractioned heparin (5000 to 10000 
units twice daily) during pregnancy appears to be efficacious  
Also low molecular weight heparin with low dose asprin in recurrent 
pregnancy loss with APS appears to be efficacious 
If a venous thromboembolic event occurs during the index pregnancy 
post hospitalization management requires therapeutic anti coagulation: 
  
 UFH :10000 to 15000 U s.c every 8 to 12hrs (monitor to keep aPTT 
1.5 to 2.5 times normal) 
 LMWH: enoxaparan 40 to 80 mg s.c twice a day or dalteparin 5000 
to 10000 U s.c twice a day (monitor Xa levels in third trimester) 
If there is personal history of thromboembolic events or strong family 
history, treat with therapeutic anti coagulation 
Post partum anti coagulation should be continued for 6 to 12 weeks- 
this does not interfere with breast feeding. 
 
IMMUNOSUPRESSIVE THERAPY: 
IV Ig therapy: Based on a large number of studies , ther remains a 
inconclusive evidence to suggest that use of IVIg in the treatment of 
patients with unexplained pregnancy loss has any benefit. 
 
PROGESTERONE THERAPY: 
A number of studies demonstrates that progesterone either inhibits 
TH1 immunity or causes a shift from TH1 to TH2 type responses 
Intra lipid infusion and TNFα inhibition therapy for treatment of 
recurrent pregnancy loss should only be administered under an 
institutional review board approved protocol. 
 
  
PREDNISOLONE THERAPY :    
Pregnancy outcomes  for treated and control patients were similar . 
However the incidence of maternal diabetes and hypertension and the 
risk of premature delivery were all increased among those with treated 
with prednisolone and aspirin. 
                                                                                                                                                                     
 
 
 
 
 
 
 
 
 
 
 
 
  
FOLIC ACID METABOLISM  
 
 
 
 
 
  
CAUSES OF FOLIC ACID DEFICIENCY: 
 Decrease in folate adequacy 
 Impending folate deficiency 
 Overt folate deficiency 
ADVERSE EFFECTS OF FOLIC ACID DEFICIENCY: 
 Defective maturation of red blood cells. 
 Megaloblastic anaemia.    
 Cardiovascular diseases along with homocystienuria. 
 Stroke. 
 Infertility. 
 Recurrent pregnancy losses due to neural tube defects. 
 
 
 
  
NEURAL TUBE DEFECTS: 
 Neural tube :  The neural plate undergoes a change in shape to create 
and infolding and closure to form the neural tube.  
 This structure develops into brain and spinal cord. 
 Neural tube closure occurs between 22 and 28 days after conception 
 Develops during first weeks of pregnancy (6 weeks after last menstrual 
period) 
 Neural tube defects are a group of congenital birth defects that affect 
the central nervous system viz. spina bifida, anencephaly, 
encephalocele. 
 Most common types are spina bifida and anencephaly 
INCIDENCE 
Spina bifida – 54 live births/yr 
Anencephaly – 13live births/yr 
Encephalocele – 13 live births/yr 
  
 
 
 
SPINA BIFIDA 
  Maldevelopment of neural tube in the lower part ( spine ) 
 It is characterized by protrusion of spinal cord components outside the 
body 
 Most common region- lumbar or lumbosacral 
 
 
  
ANENCEPHALY: 
 It results from improper development of the upper portion of the neural 
tube (brain) 
 It is a fatal condition, characterized by severe mal formation of the 
brain accompanied by facial abnormalities and absence of the skull 
 Many anencephaly affect pregnancies result in mis carriage and infants 
born with this condition die soon after birth (few hours to a few days) 
 
ENCEPHALOCELE: 
 It is a condition in which the brain protrude outside the skull in a sac of 
skin 
 Children born with encephalocele usually live but suffer from mental 
disabilities.10% of neuraltube defects  are due to encephalocoele 
 
CAUSES OF NEURAL TUBE DEFECTS 
 Spontaneous development ( multi factorial-genes, environment) 
 Chromosomal abnormalities (10 to 15%), genetic syndromes ( 3%) 
 Nutritional folate deficiency (50%), inherited disorder of folate 
metabolism 
 Maternal conditions, medications (teratogens- 1.5%) 
 
  
MATERNAL RISK FACTORS 
 Lower socio economic status 
 Prior NTD- affected pregnancy 
 Use of anti seizure treatment 
 Poorly controlled insulin dependent diabetes 
 Ethnicity  
 
RISK OF RECURRENCE: 
 For a mother who has NTD (1 in 25). 
 For a couple with prior affected pregnancy (1 in 25) 
 For a couple with two prior affected pregnancies (1 in 10) 
 
FOLIC ACID DEFICIENCY DUE TO MEDICATIONS: 
 Valproic acid 
 Metformin 
 Trimethoprim 
 Methotrexate 
 
 
 
 
  
PREVENTION OF NEURAL TUBE DEFECTS  
 50 to 70% of NTDs can be prevented by consumption of 400µ gms of 
synthetic folic acid per day 
 Also consumption of folic acid from supplements or fortified foods 
 Food rich in folate levels: 
 Low in calories  
 Low in fat 
 Cholesterol free 
 Rich in other vitamins and minerals viz. beta carotene, vit c, 
phytonutrients. 
 
 
  
 
 
PATHOPHYSIOLOGY OF HOMOCYSTEINE METABOLISM: 
        Homocysteine metabolism altered in young patients with myocardial 
infarctionand MTHFR C667Thomozygosity [shwartz et al]. 
                              Homocysteine increased levels    
      endothelial dysfunction    
                              vessel dilatation     
 Defective chorinic vascularisation is associated with embryonic death.
  
  Diagnosed byhistopathology and image analysis system and cd34 
Immunohistocnemistry[tevel de et al].      
 Parameters studied inthis placenta are      
1. median vascular area      
2. perimeter  
3. number of vascular elements and measured chorionic area 
median area perimeter and diameter are measured per vascular 
elemaent in relation to   maternal   plasma  homocysteine levels. 
HOMOCYSTEINE AND PREGNANCY COMPLICATIONS 
RECURRENT MISCARRIAGE 
Wouters et al. were the first to report the association between HHCh 
and repeated miscarriage. 14% of women –primaryrepeated miscarriage  
while 33%of patients - secondary repeated miscarriage (after having had 
normal pregnancies) had HHCh. Studies says that damage to the decidual or 
chorionic vessels,and thus disrupts the implantation .Quere et al.[83] reported 
that, in a retrospective review of 100 patients presenting with a clinical 
picture of repeated miscarriage, 12% had HHCh, 20% were homozygotes for 
the thermolabile mutation of MTHFR, and 15% had low levels of folic acid. 
           
 
 
  
HOMOCYSTEINE AND PREECLAMPSIA 
Vascular pathway along with vitamin B12 and folic acid  also affects 
pregnancy outcome. 
In this study – made in ahmedabad vitamin B12, homocysteine , folic 
acid levels are measured using fluorescence polarized immunoassay . 
Maternal uteroplacental circulation and fetal umbilical placental 
circulation are affected and vascular damage occurs.  
Study group comprises 40 antenatal women divided into two groups. 
GROUP 1: 28 to 40 weeks of gestation. 
GROUP 2: 36to 40 weeks of gestation. 
Each group divided into two divisions. 
FIRST DIVISION: 20 women with normotensive. 
SECOND DIVISION: 20 women with BP > 140/90 along with 
proteinuria. 
Results: 
P value < 0. 05 between control and study group , which is more 
significant. 
P value < 0.001between study group 1 and 2 , which is also significant. 
INFERENCE: Homocysteine- 5- 15 µmol/ L as normal value. 
Study group 1- 13.45 +/- 4.40  
Study group 2- 19.96 +/- 6.43 
  
-all these findings are supported by walker et al. [2]   
 Increased homocysteine levels are seen in patients with pre- 
eclampsia where conversion of spiral arteries from highly tortuous 
thickened walls to flaccid sinusoidal contents of low resistance 
occurs. So  muscular coats of spiral arteries are retained and more 
susceptible to hprmonal , maternal and neuronal constrictor 
influences( singh urmila et al).[1] 
Power et al[ 3]– analysis shows that increased homocysteine levels in 
eclamptic patients. 
Hogg et al[4] – also says that increased homocysteine levels in 
pregnancy induced hypertension and pre-eclampsia. 
HOMOCYSTEINE LEVELS AND P VALUES:  
Homocysteine levels correlate with severity of pre-eclampsia and 
Pvalue <0.017 which is more significant( Gupta et al).[1] 
Lvoz et al – studied homocysteine levels in normal and pre-eclamptic 
patients and showed that homocysteine levels are increased in pre-
eclamptic patients with P value 0.05. 
Cottal M.Mulley et al and Truding BJ et al – also support the same 
findings.[12,115] 
  
Area et al – folic acid , B 12, homocysteine are studied in pre-
eclamptic patients which shows that increased homocysteine levels in 
pre- eclamptic women suggest endothelial damage. 
HOMOCYSTEINE AND IUGR: 
 Most common cause for fetal growth restriction is maternal 
hypertension and especially pre-eclampsia. Growth restriction may be 
isolated or in association with pre-eclampsia. This affects 5 to 10% of 
all pregnancies. 
Increased homocysteine levels in severe pre-eclampsia causes IUGR 
which suggests highly significant poisitive correlation between 
homocysteine and asymmetric di-methyl arginine(ADMA) 
- all these are supported Lind Bled et al and Mao et al.[115,116] 
FACTORS ASSOCIATED WITH EARLY PREGNANCY LOSS: 
 Factor ᴠ leiden mutation 
 Activated protein c resistance 
 Prothrombin G20210A mutation 
 Protein s mutation 
 MTHFR mutation, protein c and anti-thrombin deficiencies.[9] 
 
 
 
  
HOMOCYSTEINE AND ABRUPTION PLACENTA 
Hyperhomacysteinemia  induce endothelial cell injury and 
disfunction leads  to thrombiembolism and defects within placenta 
vascular  bed(devries et al 1997)[19] 
Smoking also increases homocysteine levels in placenta  
Nicotine  
Vasoconstrictor effect on utrine artery and amblical artery  
Hence carboxyhemoglobin interferes with oxygenation  
Nicotin and carbon monoxide croses placenta and levels increases in 
fetal circulation 15% higher than blood levels (luck et al 1985,andres 
et al2000) 
Concentration of nicotine in amniotic fluid is 88% higher than in 
maternal  plasma (luck et al 1985 ) 
Homocysteine ,aproduct in the metabolism of essential amino acid 
methionine (steeger theunissen et al 2004 )[94]and this metabolism 
involves 5,10 mthfr,  folate,vitamin b6 , vit B12 (ray and laskin 1999, 
eskes 2001)[23,24,73,114] 
Increased homocysteine levels causes endothelial cell injury and 
endothelial dysfunction leadin on to thromboembolism (de vries et 
al)[19] 
  
There is an association factor between hyper homocystemia and 
placental abruption (goddgin wessel et al 1997, ray and laskin 1999, 
vollet et al 2000, steegers theunissen 2004)[94,114,113] 
Folate deficiency is also a risk factor for placental abruption. Those 
who do not use folic and multi vitamin tablets had 26% increased risk 
for placental abruption (nilsen et al 2008). 15 to 20%  of placental 
abruption attributable to smoking (arananth et al 1999). Inherited and 
acquired thrombophilias increase risk of venous thrombo embolism 
and adverse pregnancy outcome.  
Kupfer mine et al 1999 says that patients with preeclampsia IUGR 
still births, placental abruption had heritable or acquired 
thrombophilias 
  Thrombophilias associated with abruption include  
• MTHFR defeciency  
• Heterozygous factor 5 leiden mutation (kupfer mine 
et al 1999, faahinnet robertson et al) 
• Prothrombin gene mutation 
• Protein C & S deficiency 
• Lupus anticoagulant 
• Anti cardiolipin antibodies (oyelese, anaanth 2006) 
  
• Homozygous MTHFR point mutation 677C to T 
transition associated with placental abruption (ray 
and laskin et al 1999, eakes 2001, muk et al 
2004)[24,114] 
In finnish study, M3857 polymorphism is seen in factor 5 gene mutation 
Hyperhomocystenimia along with thrombophilias incresces risk of placental 
abruption 3 - 7 fold (eskes 2001)24 
 
FETAL DEATH 
Burke et al did however observe a 12% miscarriage rate and 10% perinatal 
death rate in the frequency of fetal death after supplementation with folic acid 
and multivitamins in a general population. 
 
NEURAL TUBE DEFECTS 
The association between neural tube defects (NTDs) and HHCh. 
 NTDs are not due to a direct action of HC, but indirectly due to a functional 
abnormality of methionine synthetase. 
 Folic acid deficiency and congenital abnormalities of MTHFR can both be 
responsible for NTDs and for HHCh. [94] 
 
 
  
WHO ARE ALL THE PATIENTS TO BE TESTED FOR 
HOMOCYSTEINE LEVELS?? 
• Unexplained blood clots 
• Unexplained atherosclerosis 
• Coronary heart disease  
• Heart attack  
• Stroke. 
WHO ARE ALL THE PATIENTS TO BE SCREENED FOR MTHFR 
MUTATION?? 
Previous history of women with birth of spina bifida and anencephaly 
child- can be screened.Ther is no specific indication to perform 
MTHFR genetic testing. Immaterial of mutation , dietary intervention 
per se and supplementation with vitamin B12 , B6 and folic acid is 
sufficient.  
HOW CAN YOU LOWER HOMOCYSTEINE LEVELS??   
 Good source folate in fruits and vegetables,  
 fortified breads,  
 Lentis 
 Chick peas 
 Asparagus 
  
 Spinach and 
 Most beans – all these supplements will break down 
homocysteine levels in blood and thus homocysteine levels 
decreases. 
 0.4mg of folic acid tablet decreases neural tube defects. 
 4 mg of folic acid tablets recommended for elevated 
homocysteine levels.[Erickson et al 72] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
STUDY DETAIL 
This study was conducted over a period of 12 months at 
department of Obstetrics and Gynaecology, Govt.R.S.R.M. Lying in 
Hospital attached to STANLEY MEDICAL COLLEGE, Royapuram, 
Chennai. 
STUDY PERIOD 
The period of study was from JANUARY 2015 – DECEMBER 2015 
STUDY DESIGN 
Observational study 
METHODOLOGY 
• Study population includes patients  with pregnancy loss within 13 
weeks of menstrual age 
• To measure fasting homo cysteine & folic acid levels 
 
INCLUSION CRITERIA 
CASES –  
• Patients  with pregnancy loss within 13 weeks of menstrual age  
CONTROLS – 
• Patients attending ante natal outpatient department who had at 
least one live child with no history of previous abortions. 
  
JUSTIFICATION  INCREASED homocystine and DECREASED folic 
acid level in patients with pregnancy loss & treating patients with FOLIC 
ACID & Multi VIT tablets. 
 
EXCLUSION CRITERIA 
Patients with  
• Increased serum creatinine 
• Increased serum alanine amino transferase 
• Ectopic pregnancy  
• Molar pregnancy 
• Chronic hyper tension 
• Diabetes mellitus 
• Preexisting liver or renal disorder 
• History of thromboembolism 
• Abruptio placenta 
• Pre term labour 
• Anemia  
• Smoking 
• B12 & folic acid supplementation 
 
  
All pregnancies to be confirmed by a positive urinary hCG test or 
ultrasound imaging. 
• Fasting Blood sample taken after obtaining consent from the 
Patient 
• For those with elevated homocysteine B6 and B12 added along with folic 
acid tablets 
• Pedigree analysis of the patients done detail 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
MATERIAL AND METHODS 
 
Between JANUARY 2015 to DECEMBER 2015, 100 women who 
suffered early pregnancy losses, attending our genetic clinic and antenatal OP 
were evaluated clinically and 100 women were enrolled for this study. 
Pregnancy Loss within 13 weeks gestation is enrolled in my study with 
confirmation by biochemical pregnancy test [β-human chorionic 
gonadotrophin (HCG 100 IU/l] and/or sonography. Ectopic pregnancies or 
elective terminations of gestations were excluded. They were categorized as 
primary and secondary aborters, based on whether they had atleast one 
pregnancy beyond 16 weeks of gestational age. A control group of 100 
women with normal menstrual history and an obstetric history of 
uncomplicated pregnancies along with atleast one live child. All pregnancies 
confirmed by a positive urinary hCG test or ultrasound imaging. Detailed 
history with pedigree analysis done. The patients and controls did not take 
any vitamin B supplementation or oral contraceptives 6 months before 
performing homocysteine test. Fasting EDTA Blood sample was taken after 
obtaining informed consent from the patient at 0800 hours. 
 
Homocysteine levels were measured after overnight fasting.Women 
were excluded if they had elevated serum creatinine or SGOT.None of the 
  
subjects of either the study or the control group had a known endocrine 
dysfunction or suffered from gastrointestinal, hepatobiliary, renal or vascular 
disease. Patients with neurological disorders such as epilepsy were also 
excluded. Before admittance,informed consent was obtained from all 
subjects. 
 
In four women other investigations revealed abnormalities like thyroid 
dysfunction, gestational diabetes, bicornuate uterus etc. Total homocysteine 
concentration was measured by enzymatic photometric method, after 
centrifugation and storing. out of 100 Patients, 21 women were considered 
hyperhomocysteinemic and 41 women with decreased folic acid levels. These 
patients started on oral folicacid supplementation. For those with elevated 
homocysteine, vitamin B6 and B12 were added. 
 
Results are given as Mean, Median, Standard Deviation (SD). 95% 
confidence interval was also calculated. Consequently statistical significance 
was determined using F-test, Pearson Chi square test, Fischer linear test. A p- 
value <0.001 was considered to be a highly significant value.   
  
RESULTS AND ANALYSIS 
Age in years * Group 
    Group Total P VALUE 
 
 
 
 
 
 
 
0.481 
    Control Cases   
 18-20 Count 13 7 20 
 
 
 
 
 
 
 
 
       AGE IN 
YEARS 
  % within Age 
in years 65.0% 35.0% 100.0% 
  % within 
Group 13.0% 7.0% 10.0% 
21-25 Count 31 37 68 
  % within Age 
in years 45.6% 54.4% 100.0% 
  % within 
Group 31.0% 37.0% 34.0% 
26-30 Count 42 39 81 
  % within Age 
in years 51.9% 48.1% 100.0% 
  % within 
Group 42.0% 39.0% 40.5% 
31-35 Count 13 14 27 
  % within Age 
in years 48.1% 51.9% 100.0% 
  % within 
Group 13.0% 14.0% 13.5% 
36-40 Count 1 3 4 
  % within Age 
in years 25.0% 75.0% 100.0% 
  % within 
Group 1.0% 3.0% 2.0% 
Total Count 100 100 200 
  % within Age 
in years 50.0% 50.0% 100.0% 
  % within 
Group 100.0% 100.0% 100.0% 
This table shows age in years comparison in  which higher no of women falls 
in 25- 30 yrs and shows pvalue  of 0.4 which is not much significant 
  
Homocysteine * Group 
 
    Group Total P 
VALUE 
 
 
 
 
 
 
 
 
 
 
 
      **             
<0.001 
 
 
 
    Control Cases   
 
 
 
 
 
 
 
 
Homocysteine 
 
  
  
  
  
  
  
  
  
  
  
Normal Count 100 76 176 
  % within 
Homocystein
e 
56.8% 43.2% 100.0% 
  % within 
Group 100.0% 76.0% 88.0% 
Mild Count 0 15 15 
  % within 
Homocystein
e 
.0% 100.0% 100.0% 
  % within 
Group .0% 15.0% 7.5% 
Moderate Count 0 8 8 
  % within 
Homocystein
e 
.0% 100.0% 100.0% 
  % within 
Group .0% 8.0% 4.0% 
Severe Count 0 1 1 
  % within 
Homocystein
e 
.0% 100.0% 100.0% 
  % within 
Group .0% 1.0% .5% 
Total Count 100 100 200 
  % within 
Homocysteine 50.0% 50.0% 100.0% 
  % within Group 100.0% 100.0% 100.0% 
 
This table shows homocysteine group with cases and controls and pvalue is 
0.001 which is more significant. 
  
  
 
 
 
 
 
  
Homocysteine
SevereModerateMildNormal
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n
t
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Folic Acid * Group 
 
  
This tabular column shows folic acid group with cases and controls in which 
is more significant <0.001 
 
   Group Total P 
VALUE 
 
 
 
 
 
0.001 
    Control Cases   
Folic Acid Normal Count 100 76 176 
    % within Folic 
Acid 56.8% 43.2% 100.0% 
    % within Group 100.0% 76.0% 88.0% 
  Decreased Count 0 24 24 
    % within Folic 
Acid .0% 100.0% 100.0% 
    % within Group .0% 24.0% 12.0% 
Total Count 100 100 200 
  % within Folic 
Acid 50.0% 50.0% 100.0% 
  % within Group 100.0% 100.0% 100.0% 
  
 
 
 
 
 
 
 
T-Test 
Folic Acid
DecreasedNormal
Co
u
n
t
120
100
80
60
40
20
0
Group
Control
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 Group Statistics 
 
  Group N Mean Std. Deviation P VALUE 
0.205 Age in years Control 100 25.76 4.274 
  Cases 100 26.54 4.400 
Independent Samples Test 
 
    
Levene's Test 
for Equality of 
Variances t-test for Equality of Means 
    F Sig. T df 
Sig. (2-
tailed) 
Mean 
Differe
nce 
Std. 
Error 
Differe
nce 
95% 
Confidence 
Interval of the 
Difference 
                  Lower Upper 
Age in 
years 
Equal 
variances 
assumed 
.030 .864 -1.272 198 .205 -.78 .613 -1.990 .430 
  Equal 
variances 
not 
assumed 
    -1.272 197.832 .205 -.78 .613 -1.990 .430 
 
T-Test 
  
 Group Statistics 
 
  Group N Mean 
Std. 
Deviation P VALUE 
Homocysteine Control 100 10.187 2.5718  
  Cases 100 13.847 12.0395 0.003 
 
Homocysteine levels with mean and standard deviation are compared and p 
value is more significant 0.003 
 
 
 
 
 
 
 
 
T-Test 
  
 
 Group Statistics 
 
  Group N Mean Std. Deviation P VALUE 
Folic Acid Control 
100 13.916 3.7312 
 
0.001 
  Cases 100 11.847 5.1291  
 
  
  
Independent Samples Test 
 
    
Levene's Test for 
Equality of 
Variances t-test for Equality of Means 
    F Sig. T df 
Sig. (2-
tailed) 
Mean 
Differe
nce 
Std. Error 
Differenc
e 
95% Confidence 
Interval of the 
Difference 
                  Lower Upper 
Folic Acid Equal 
variances 
assumed 13.510 .000 3.262 198 .001 2.069 .6343 .8181 3.3197 
  Equal 
variances 
not 
assumed 
    3.262 180.856 .001 2.069 .6343 .8174 3.3204 
 
 
 
 
 
  
Oneway 
 
Descriptives 
 
Homocysteine  
 No of 
abortion N Mean Std. Deviation 
P VALUE 
 
 
 
<0.001 
        
1 24 9.199 4.0682 
2 32 11.947 6.2198 
3 24 12.512 7.1332 
4 20 24.065 21.5635 
Total 100 13.847 12.0395 
This tabular column based on number of abortions in  homocysteine group. 
mean and standard deviation values are calculated and pvalue is 0.001.  
 
  
 
 
  
ANOVA 
 
Homocysteine 
  
  
Sum of 
Squares df Mean Square F Sig. 
Between Groups 2765.088 3 921.696 7.638 .001 
Within Groups 11584.918 96 120.676     
Total 14350.006 99       
Sum of squares and mean squares are calculated and p value is more 
significant 
  
  
Post Hoc Tests 
Multiple Comparisons 
Dependent Variable: Homocysteine  
Tukey HSD  
(I) Number of 
abortion 
(J) Number of 
abortion 
Mean 
Difference 
(I-J) Std. Error Sig. 95% Confidence Interval 
          Lower Bound Upper Bound 
1 2 -2.748 2.9664 .791 -10.504 5.008 
  3 -3.313 3.1712 .724 -11.605 4.978 
  4 -14.866(*) 3.3260 .000 -23.562 -6.170 
2 1 2.748 2.9664 .791 -5.008 10.504 
  3 -.566 2.9664 .998 -8.321 7.190 
  4 -12.119(*) 3.1313 .001 -20.306 -3.932 
3 1 3.313 3.1712 .724 -4.978 11.605 
  2 .566 2.9664 .998 -7.190 8.321 
  4 -11.553(*) 3.3260 .004 -20.249 -2.857 
4 1 14.866(*) 3.3260 .000 6.170 23.562 
  2 12.119(*) 3.1313 .001 3.932 20.306 
  3 11.553(*) 3.3260 .004 2.857 20.249 
. 
  
Homogeneous Subsets 
Homocysteine 
Tukey HSD  
Number of abortion N Subset for alpha = .05 
    1 2 
1 24 9.199   
2 32 11.947   
3 24 12.512   
4 20   24.065 
Sig.   .720 1.000 
 
 
 
 
 
 
 
  
Oneway 
 
Descriptives 
 
Folic Acid  
  N Mean Std. Deviation 
P VALUE 
 
 
0.004 
1 24 13.268 4.0356 
2 32 12.511 5.3019 
3 24 12.564 5.0072 
4 20 8.221 4.8333 
Total 100 11.848 5.1291 
Folic acid group shows mean and standard deviation values in which pvalue 
are calculated 0.004which is more significant 
 
  
 
 
 
  
ANOVA 
 
Folic Acid  
  
Sum of 
Squares df Mean Square F Sig. 
Between 
Groups 337.978 3 112.659 4.772 .004 
Within Groups 2266.518 96 23.610     
Total 2604.496 99       
 
 
 
 
 
 
 
 
 
  
Post Hoc Tests 
Multiple Comparisons 
Dependent Variable: Folic Acid  
Tukey HSD  
(I) Number of 
abortion 
(J) Number of 
abortion 
Mean 
Difference 
(I-J) Std. Error Sig. 95% Confidence Interval 
          Lower Bound Upper Bound 
1 2 .757 1.3121 .939 -2.673 4.188 
  3 .704 1.4027 .958 -2.963 4.372 
  4 5.048(*) 1.4711 .005 1.201 8.894 
2 1 -.757 1.3121 .939 -4.188 2.673 
  3 -.053 1.3121 1.000 -3.483 3.378 
  4 4.291(*) 1.3850 .013 .669 7.912 
3 1 -.704 1.4027 .958 -4.372 2.963 
  2 .053 1.3121 1.000 -3.378 3.483 
  4 4.344(*) 1.4711 .020 .497 8.190 
4 1 -5.048(*) 1.4711 .005 -8.894 -1.201 
  2 -4.291(*) 1.3850 .013 -7.912 -.669 
  3 -4.344(*) 1.4711 .020 -8.190 -.497 
  
Homogeneous Subsets 
 Folic Acid 
Tukey HSD  
Number of abortion N Subset for alpha = .05 
    1 2 
4 20 8.221   
2 32   12.511 
3 24   12.564 
1 24   13.268 
Sig.   1.000 .948 
 
 
 
 
 
 
 
Frequencies 
  
Age in years 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 18-20 20 10.0 10.0 10.0 
  21-25 68 34.0 34.0 44.0 
  26-30 81 40.5 40.5 84.5 
  31-35 27 13.5 13.5 98.0 
  36-40 4 2.0 2.0 100.0 
  Total 200 100.0 100.0   
Number of abortion 
 
  Frequency Percent 
Valid 1 24 24.0 
  2 32 32.0 
  3 24 24.0 
  4 20 20.0 
  Total 100 100.0 
 
  
Homocysteine 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Normal 176 88.0 88.0 88.0 
  Mild 15 7.5 7.5 95.5 
  Moderate 8 4.0 4.0 99.5 
  Severe 1 .5 .5 100.0 
  Total 200 100.0 100.0   
 
In homocysteine group cumulative  percentage is calculated .mild levels 
shows 95%moderate levels shows 99.5%.severe levels shows 100 % 
  
 
 
 
 
 
 
  
Folic Acid 
 
  Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid Normal 176 88.0 88.0 88.0 
  Decrease
d 24 12.0 12.0 100.0 
  Total 200 100.0 100.0   
Cumulative percentage for folic acid levels are calculated which shows 
88%among normal patientsand  decreased folic acid levels shows 100% 
 
 
  
  
DISCUSSION 
Multiple mechanisms play a role in the etiology of pregnancy loss , viz 
-Immunological disorders 
-Genetic disorders 
-Endocrine disorders 
-Psychological disorders 
-Inherited disorders 
- are responsible for embryo loss( Bulleti.,et al…1996). 
• Moderate hyperhomocysteinemia also found to be risk factor for 
recurrent pregnancy loss(steegers Thunissen..et al -1992;Wouer et 
al…1993;Del Biaco et al…2004).[94] 
• Hyperhomocysteinemia shows an increased risk in causing recurrent 
pregnancy loss – confirmed meta analysis report( Nelen et 
al…2000).[23,24] 
• Lowering homocysteine concentration by vitamin B12 
supplementation, shows a positive effect in several cases.  
• After a few months of treatment, spontaneous pregnancies occurs in 
those patients who had previous pregnany loss (Quere et 
al..1998,2001;Candito et al…2003;Gueant et al…2004).[46,84,85,83] 
  
• Daily supplementation with vitamin B12 and folic acid- redeuce 
homocysteine concentration (Homocysteine lowering collaboration- 
American Journal). 
• Regarding MTHFR mutation , treatment is dietary intervention and 
supplementation with folic acid and vitamin B group. 
• The amount depends upon the degree homocysteine elevation. 
• Many unknowns remain regarding the impact of 
hyperhomocysteinemia pregnancy.  
• Large scale of study and control groups needed to define relation 
between homocysteine , folic acid and pregnancy loss. 
 
  
  
SUMMARY 
• Our study comprises 100 recurrent pregnancy loss cases and 100 
control cases. 
• Out of 100 cases, 21 patients shows increased homocysteine levels 
and 24 patients shows decreased folic acid levels. 
• Homocysteine group shows P value of 0.001, which is significant at 
1% levels. 
• Also folic acid group shows P value 0.001, which is also highly 
significant. 
• In patients with increased homocysteine levels , vitamin B6 , 
vitamin B 12 along with folic acid tablets are given. 
• This study shows there is no correlation of age with 
hyperhomocysteinemia and decresed folic acid levels. 
  
  
CONCLUSION 
 
Recent studies on early pregnancy loss and hyperhomocysteinemia suggested 
a positive association between the two.In the present study elevated fasting 
homocysteine concentrations along with decreased folic acid levels were 
associated with early pregnancy losses. The level showed no significant 
difference in ages.In my study Homocysteine group and folic acid group 
show a significant p value of less than 0.001. In animal studies folic acid 
supplementation seemed to improve survival of fetuses during early 
gestations and increases the number of living fetuses.In our study also folic 
acid supplementation along with B12 and B6 has an effect on lowering the 
homocysteinebut the still more studies are needed to conclude the effect of 
folic acid B6,B12 on pregnancy outcome.Still more intervention trials as well 
as prospective studies measuring folate and tHcy status before and during 
pregnancy are needed to establish the role of folic acid B6 and B12 either as 
predictors or etiologic factors for recurrent pregnancy losses. 
We therefore believe that women with hyperhomocysteinemia should 
be identified earlier. The folic acid-vitamin B6,B12 combination, a 
nonteratogenic treatment, should be tried. As suggested by our case report, 
therapeutic normalization of hyperhomocysteinemia might lead to metabolic 
restoration, which may favor a successful pregnancy outcome.  
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MASTER CHART 
S 
NO NAME AGE 
IP NO 
ABORTION 
LMP EDD 
HOMOCYSTEINE FOLIC ACID 
1.
Mrs.shyamala 20 18193 G2A1 21/04/15 28/01/16 22.9 4.1 
2.
Mrs.vinodha 23 19312 G3P1A2 28/02/15 07/12/15 8.6 7.2 
3.
Mrs.Radha 27 20341 G3P1A1 03/03/15 10/12/15 5.3 11.2 
4.
Mrs.Pinky 24 21333 G4P1A2 05/04/15 12/01/16 23.5 6 
5.
Mrs.Rinomary 27 20001 G5P2A3 27/04/15 04/01/16 11.9 12.3 
6.
Mrs.Gowri 23 18333 G6L1A4 10/04/15 17/01/16 32.1 4.2 
7.
Mrs.Lakshmi 22 18111 G4P1A2 07/04/15 14/01/16 20.2 5.3 
8.
Mrs.Gayathri 20 19771 G3L1A1 08/02/15 15/11/15 9.1 14.6 
9.
Mrs.Abinaya 24 18833 G5A4 15/02/15 22/11/15 8.8 10.3 
10.
Mrs.Durdana 25 18343 G3A1 17/05/15 24/02/16 7.3 15.2 
11.
Mrs.Bavani 30 22114 G4L1A2 01/06/15 08/03/16 9.3 16.2 
12.
Mrs.Mythra 33 23221 G3P1A1 03/02/15 10/01/15 9.1 8.9 
13.
Mrs.Ragavi 29 24233 G4P1A2 19/04/15 26/01/16 13.3 12.3 
14.
Mrs.Parveen 27 26112 G5A4 01/05/15 08/02/16 16 4.5 
15.
Mrs.Pavithra 30 22111 G6P2A4 10/05/15 17/02/16 31.8 3.5 
16.
Mrs.Saranya 22 19771 G5P1A3 28/04/15 05/02/16 10.1 16.2 
17.
Mrs.Keerthana 28 15431 G6P2L1A2 26/04/15 03/02/16 6.8 18.2 
18.
Mrs.Kavya 26 12309 G7P2L1A4 18/04/15 25/01/15 34.5 3.14 
19.
Mrs.Karthiga 35 32423 G5A3 04/03/15 11/12/15 12.6 19.2 
20.
Mrs.Halima 26 17834 G6P2L2A4 15/01/15 22/10/15 4.9 15.3 
21.
Mrs.Vasantha 28 12345 G3P1A2 01/02/15 08/11/15 8.4 13.3 
22.
Mrs.Muniyammal 20 11231 G4P1L1A1 21/01/15 28/10/15 6.3 12.09 
23.
Mrs.Mahimaimary 24 15234 G2A1 03/03/15 10/12/15 3.6 12.5 
24.
Mrs.Baby    20 18122 G4P1A2 08/01/15 15/10/15 13.8 15.5 
25.
Mrs.Allirani 28 18001 G4P1A4 16/01/15 23/10/15 6.5 16.2 
26.
Mrs.Mahweswari 32 16444 G5P2L1A3 22/01/15 28/10/15 7.6 10.3 
27.
Mrs.Vani 25 16577   G6P1A3 26/02/15 05/12/15 11.9 17.9 
28.
Mrs.Ramya 32 15431 G4A3 17/02/15 24/11/15 7.4 14.9 
29.
Mrs.Naomi 40 14365 G3P1A1 21/03/15 28/12/15 5.3 12.8 
30.
Mrs.Kameswari 27 11232 G3P1A2 03/01/15 10/10/15 11.6 7.8 
31.
Mrs.Ramani 26 13670 G4A3 07/02/15 14/11/15 26.1 3.54 
32.
Mrs.Janaki 22 18141 G3A2 28/01/15 05/11/15 7.5 13.56 
33.
Mrs.Revathy 25 17494 G4P1L1A2 09/02/15 16/11/15 6.9 15.14 
34.
Mrs.Jeyanthi 29 16577 G5A3 15/01/15 22/10/15 4.7 16.3 
35.
Mrs.Mary 23 21356 G6P2L1A3 10/02/15 17/11/15 12.5 18.5 
36.
Mrs.Latha 21 23415 G4A2 05/03/15 12/12/15 10.4 19.21 
37.
Mrs.Muthammal 24 18345 G3P1A1 12/12/14 19/09/15 11.5 10.34 
38.
Mrs.SelvI    36 26445 G5A4 27/12/14 03/09/15 8.9 9.47 
39.
Mrs.Radhika 38 22111 G6P1L1A3 01/12/14 08/09/15 6.2 16.23 
40.
Mrs.Anitha 29 24232 G5A4 08/12/14 15/09/15 35.9 5.2 
41.
Mrs.Ramya 27 20003 G3P1A1 10/01/15 17/10/15 10.4 19.9 
42.
Mrs.Nithya 25 20112 G3A1 31/01/15 07/10/15 9.5 11.8 
43.
Mrs.suseela 24 17256 G4P1A2 28/02/15 07/11/15 10.5 19.1 
44.
Mrs.Tamilmalar 28 32849 G5P2L1A2 04/04/15 11/01/16 11.5 16.6 
45.
Mrs.Reshma 28 19837 G4L0A4 26/04/15 02/02/16 26.3 6.1 
46.
Mrs.Nisha 20 23840 G6P2L1A2 11/04/15 18/12/15 8.5 15.6 
47.
Mrs.jahabart 35 23423 G5A3 28/03/15 04/12/15 7.1 14.8 
48.
Mrs.Nivedha 30 23188 G3P2A1 16/03/15 23/12/15 11.5 18.3 
49.
Mrs.Shanthi 25 14465 G4P1L1A2 11/01/15 18/10/15 9.1 19.6 
50.
Mrs.Vinodhini 22 13324 G2P1A1 01/02/15 08/11/15 7.9 12.9 
51.
Mrs.shalini 21 18234 G4P1A3 30/04/15 07/02/15 10.5 15.5 
52.
Mrs.Vathsala 31 21342 G4A2 02/02/15 09/11/15 32.4 4.8 
53.
Mrs.Sheela 29 21132 G5P1L1A2 01/04/15 08/01/15 6.12 15.15 
54.
Mrs.Gomathi 17 15345 G3P1A1 02/12/15 09/11/15 5.9 10.1 
55.
Mrs.Nishanthini 24 19232 G5A4 03/05/15 10/02/16 13.7 9.9 
56.
Mrs.Devi 25 21345 G2A1 10/05/15 17/02/16 9.2 16.3 
57.
Mrs.Ragavi 22 27774 G2A1 15/05/15 22/02/16 8.45 14.56 
58.
Mrs.Nivedhitha 29 22281 G3A3 01/03/15 08/12/15 14 9.12 
59.
Mrs.Surya 28 22243 G6P2L2A4 15/02/15 22/11/15 33.51 5.9 
60.
Mrs.Kala 23 28736 G5P1L1A2 17/01/15 24/10/15 8.4 19.6 
61.
Mrs.Chandra 26 21129 G6P1L1A3 21/01/15 28/10/15 7.3 11.7 
62.
Mrs.Sulekha 27 22134 G3A2 07/02/15 14/11/15 11.7 8.9 
63.
Mrs.Lekha 22 13245 G3P1A2 09/04/15 16/01/16 7.7 7.9 
64.
Mrs.Sulochana 29 21111 G6P2A4 14/03/15 21/12/15 6.1 15.3 
65.
Mrs.Shamili 26 54388 G3A2 20/02/15 27/11/16 8.78 17.4 
66.
Mrs.Anjali 25 67234 G2A1 11/05/15 18/02/16 5.17 18.3 
67.
Mrs.Baby 31 72226 G5P1A4 15/04/15 22/01/16 37.8 4.9 
68.
Mrs.Navya 24 47388 G3P1A2 11/03/15 18/12/15 5.77 14.4 
69.
Mrs.Nirosha 26 38844 G3P1L1A1 10/05/15 17/02/16 7.88 13.6 
70.
Mrs.Basumathi 32 21345 G2A1 22/04/15 29/01/16 12.6 9.15 
71.
Mrs.Uma 25 54761 G5P1A4 07/05/15 14/02/16 13.7 10.6 
72.
Mrs.Thirupatham 22 36452 G4A3 10/05/15 17/02/16 10.4 8.9 
73.
Mrs.Manimegalai 31 32465 G5P1A2 03/06/15 10/03/16 8.3 17.3 
74.
Mrs.Joycy 19 35546 G3A1 07/01/15 14/10/15 16.78 6 
75.
Mrs.Rosy 26 62803 G2A1 21/02/15 28/11/15 7.1 16.8 
76.
Mrs.Kavitha 25 88801 G3P1A2 04/03/15 11/12/15 5.4 17.2 
77.
Mrs.Raasi 32 37465 G5P1A3 14/02/15 21/11/15 9.2 19.4 
78.
Mrs.Farhana 27 30002 G6 P1A3 05/01/15 12/10/15 30.9 3.25 
79.
Mrs.Sowmi 21 32103 G2 P1A1 16/02/15 22/11/15 8.6 12.6 
80.
Mrs.Ranjini 22 27738 G4P1A3 21/04/15 28/01/16 7.4 14.5 
81.
Mrs.aAnnejoseph 25 33390 G4P0L0A4 22/03/15 29/12/15 9.8 13.9 
82.
Mrs.Richaa 27 11322 G3P1A2 26/02/15 05/12/15 12.3 11.2 
83.
Mrs.Parveen 33 32211 G4P1A3 23/02/15 30/11/15 14.1 9.4 
84.
Mrs.Vinodhini 30 21111 G5P1A4 02/01/15 09/10/15 24.7 3.9 
85.
Mrs.Girija 35 23111 G6P2A4 15/03/15 21/12/15 13.2 15.6 
86.
Mrs.Fathima 32 12903 G3P1A1 22/04/15 29/01/16 8.8 17.3 
87.
Mrs.Chandralekha 21 21309 G4A2 03/01/15 10/10/15 18.54 3.5 
88.
Mrs.Umarani 25 21113 G3P1A1 15/01/15 21/10/15 10.6 19.1 
89.
Mrs.Praveena 27 20999 G4A3 08/04/15 15/01/16 6.7 16.7 
90.
Mrs.Gheetha 28 24551 G5P1A4 04/03/15 11/10/15 20.9 4.4 
91.
Mrs.Priya 30 21113 G6P2A3 04/02/15 11/09/15 27.3 5.3 
92.
Mrs.Keerthi 29 17677 G3P1A2 28/02/15 07/12/15 23.45 3.8 
93.
Mrs.Ramya 21 22200 G5P1A3 03/03/15 10/12/15 9.1 13.7 
94.
Mrs.Ashwini 22 27777 G3P1A2 21/02/15 28/09/15 6.8 14.3 
95.
Mrs.Nikhitha 26 22344 G4P1A2 17/02/15 24/09/15 18.2 5.6 
96.
Mrs.Jessica 28 12367 G5P1A3 04/02/15 11/11/15 11.9 9.7 
97.
Mrs.Sharon 26 16565 G3A2 03/03/15 12/12/15 10.7 14.1 
98.
Mrs.Selvambal 35 22222 G7P1A5 05/04/15 12/01/16 102.2 2.1 
99.
Mrs.Elakkiya 24 14433 G3A2 20/05/15 27/02/16 17.84 4.6 
100.
Mrs. Pushpa latha 28 28939 G5P1A3 26/03/15 03/01/16 23.4 4.2 
 
  
 
 
 
 
 
 
VALUES OF CONTROL 
  
S NO NAME AGE IP NO OBSTETRIC 
code 
LMP EDD GESTATIONAL AGE HOMOSY
STEINE 
FOLIC 
ACID 
1. Mrs mala 20 11305 G3P2L2 10/02/15 17/11/15 11 WEEKS 2 DAYS 6.8 15.1 
2. mrs amutha 22 15623 G2P1L1 05/03/15 12/12/15 10 WEEKS 2 DAYS 12 8.1 
3. mrs sangeetha 24 23343 G2P1L1 12/12/14 19/09/15 12 WEEKS 2 DAYS 11.1 16.6 
4. mrs aseena 26 12324 G2P1L1 27/12/14 03/09/15 13 WEEKS 1 DAYS 13.4 8.9 
5. mrs shoba 28 22414 G2P1L1 01/12/14 08/09/15 11 WEEKS 3 DAYS 10.3 7.8 
6. mrsvijaya 32 23412 G2P1L1 08/12/14 15/09/15 12 WEEKS 2 DAYS 8.6 16.1 
7. mrs savitha 23 34520 G3P2L2 10/01/15 17/10/15 10 WEEKS 4 DAYS 6.2 17.3 
8. mrs sumathi 26 21421 G2P1L1 31/01/15 07/10/15 11 WEEKS 6 DAYS 8.9 14.5 
9. mrs usha 27 12333 G2P1L1 28/02/15 07/11/15 13 WEEKS 3 DAYS 12.3 16.6 
10. mrs lekshmi 30 12311 G2P1L1 04/04/15 11/01/16 10 WEEKS 4 DAYS 14.3 8.9 
11. mrs malliga 19 19322 G2P1L1 26/04/15 02/02/16 12 WEEKS 2 DAYS 14.9 10.1 
12. mrs devi 24 11311 G2P1L1 11/04/15 18/12/15 12 WEEKS 6 DAYS 10.3 14.5 
13. mrs selvi 29 12221 G2P1L1 28/03/15 04/12/15 13 WEEKS 1 DAY 9.6 15.3 
14. mrs renu 30 15311 G2P1L1 16/03/15 23/12/15 11 WEEKS 4 DAYS 8.3 17.3 
15. mrs usha 35 11911 G3P2L2 11/01/15 18/10/15 11 WEEKS 2 DAYS 7.6 18.5 
16. mrs kalaivani 32 12222 G2P1L1 01/02/15 08/11/15 10 WEEKS 1 DAY 6.9 19.1 
17. mrs nirmala 26 17000 G2P1L1 30/04/15 07/02/15 13 WEEKS 3 DAYS 12.3 10.1 
18. mrs anjali 22 10011 G2P1L1 02/02/15 09/11/15 11 WEEKS 2 DAYS 13.5 16.9 
19. mrs roshima 20 11818 G2P1L1 01/04/15 08/01/15 12 WEEKS 5 DAYS 14.1 19.3 
20. mrs thulasi 19 18888 G2P1L1 02/12/15 09/11/15 13 WEEKS 9.1 19.6 
21. mrs janey 24 19119 G3P2L2 03/05/15 10/02/16 12 WEEKS 3DAYS 13.2 10.1 
22. mrs rizwana 30 18111 G2P1L1 10/05/15 17/02/16 10 WEEKS 4 DAYS 6.1 16.1 
23. mrs jeyashree 22 11231 G2P1L1 15/05/15 22/02/16 12 WEEKS 2 DAYS 7.9 17.3 
24. mrs devi 26 12222 G2P1L1 01/03/15 08/12/15 11 WEEKS 4 DAYS 7.6 9.6 
25. mrs divya 23 14333 G2P1L1 15/02/15 22/11/15 13 WEEKS 1 DAY 8.5 10.3 
26. mrs soumya 19 22125 G2P1L1 21/04/15 28/01/16  12 WEEKS 2 DAYS 11.2 11.2 
27. mrs parveen 24 21122 G2P1L1 28/02/15 07/12/15 12 WEEKS 2 DAYS 6.9 13.3 
28. mrs sujatha 26 24211 G2P1L1 03/03/15 10/12/15 11 WEEKS 14.6 14.5 
29. mrs geethmala 32 26122 G3P2L2 05/04/15 12/01/16 11 WEEKS 3 DAYS 10.6 16.7 
30. mrs arun 35 20011 G2P1L1 27/04/15 04/01/16 12 WEEKS 1DAY 8.9 19.8 
31. mrs meena 20 24112 G2P1L1 10/04/15 17/01/16  10 WEEKS 5 DAYS 12.3 10.8 
32. mrs sarala 29 25222 G2P1L1 07/04/15 14/01/16 13 WEEKS 2 DAYS 8.6 8.3 
33. mrs kalaivani 27 16589 G2P1L1 08/02/15 15/11/15 11 WEEKS 4 DAYS 13.4 7.6 
34. mrs logeshwari 19 21214 G2P1L1 15/02/15 22/11/15 12 WEEKS 5 DAYS 14.1 9.8 
35. mrs elayaveni 18 11222 G2P1L1 22/03/15 29/12/15 13 WEEKS 2 DAYS 10.3 10.3 
36. mrs vani 26 18121 G2P1L1 26/02/15 05/12/15 10 WEEKS 4 DAYS 8.9 14.6 
37. mrs anjali 34 28112 G3 P2L2 23/02/15 30/11/15 10 WEEKS 2 DAYS 13.2 13.2 
38. mrs poomethi 36 27112 G2P1L1 02/01/15 09/10/15 12 WEEKS 6 DAYS 13.9 12.9 
39. mrs booshan 26 21122 G2P1L1 15/03/15 21/12/15 11 WEEKS 3 DAYS 10.7 8.9 
40. mrs lakshaya 22 26112 G3P2L2 22/04/15 29/01/16 11 WEEKS 4 DAYS 12.7 16.6 
41. mrs lochini 20 27722 G2P1L1 03/01/15 10/10/15 11 WEEKS 2 DAYS 11.2 17.8 
42. mrs srimethi 29 21221 G2P1L1 15/01/15 21/10/15 10 WEEKS 2 DAYS 8.1 10.3 
43. mrs tamilvani 27 24112 G2P1L1 08/04/15 15/01/16 12 WEEKS 2 DAYS 11.9 16.6 
44. mrs beena 32 29112 G2P1L1 04/03/15 11/10/15 13 WEEKS 1 DAYS 7.3 12.3 
45. mrs priyamani 26 30111 G2P1L1 04/02/15 11/09/15 13 WEEKS 1 DAY 14.2 9.6 
46. mrs shobana 27 14531 G2P1L1 28/02/15 07/12/15 12 WEEKS 4 DAYS 9.6 10.3 
47. mrs baseena 23 13530 G2P1L1 03/03/15 10/12/15 13 WEEKS 1 DAY 8.6 16.7 
48. mrs nivedhana 24 15222 G3P2L2 21/02/15 28/09/15 11 WEEKS 4 DAYS 10.3 15.8 
49. mrs thara 20 15555 G2P1L1 17/02/15 24/09/15 11 WEEKS 2 DAYS 4.7 10.7 
50. mrs sultana 32 23112 G2P1L1 04/02/15 11/11/15 10 WEEKS 1 DAY 11.2 19.6 
begam 
51. mrs manimalai 23 25122 G2P1L1 03/03/15 12/12/15 13 WEEKS 3 DAYS 8.3 9.9 
52. mrs niveditha 28 27188 G2P1L1 05/04/15 12/01/16 11 WEEKS 2 DAYS 9.6 12.9 
53. mrs sunitha 25 11001 G2P1L1 20/05/15 27/02/16 12 WEEKS 5 DAYS 13.1 13.6 
54. mrs devishree 19 14361 G2P1L1 26/03/15 03/01/16 13 WEEKS 12.9 15.8 
55. mrs kavitha 18 18111 G2P1L1 17/05/15 24/02/16 12 WEEKS 3DAYS 14.3 7.9 
56. mrs renu 26 14322  01/06/15 08/03/16 10 WEEKS 4 DAYS 9.6 19.1 
57. mrs vinitha 21 21112 G3P2L2 03/02/15 10/01/15 12 WEEKS 8.6 11.3 
58. mrs vedha 27  28111 G2P1L1 19/04/15 26/01/16 13 WEEKS 4 DAYS 8.5 13.9 
59. mrs bhavani 22 25333 G2P1L1 01/05/15 08/02/16  10 WEEKS 5 DAYS 7.8 11.6 
60. mrs poongodi 30 23331 G2P1L1 10/05/15 17/02/16 13 WEEKS 2 DAYS 6.9 8.7 
61. mrs seema 26 24442 G2P1L1 28/04/15 05/02/16 11 WEEKS 4 DAYS 10.3 9.1 
62. mrs kani 23 28112 G2P1L1 26/04/15 03/02/16 12 WEEKS 5 DAYS 12.1 15.1 
63. mrs aseena 24 14322 G2P1L1 18/04/15 25/01/15 13 WEEKS 2 DAYS 7.8 8.1 
64. mrs tamilarasi 27 15322 G2P1L1 04/03/15 11/12/15 10 WEEKS 4 DAYS 7.5 16.6 
65. mrs soundarya 32 14333 G2P1L1 15/01/15 22/10/15 10 WEEKS 2 DAYS 13.5 8.9 
66. mrs datchayani 26 15322 G2P1L1 01/02/15 08/11/15 11 WEEKS 6 DAYS 13.3 7.8 
67. mrs renuga 27 14333 G2P1L1 21/01/15 28/10/15 13 WEEKS 3 DAYS 9.6 16.1 
68. mrs jayashree 29 17311 G2P1L1 03/03/15 10/12/15 10 WEEKS 4 DAYS 14.1 17.3 
69. mrs amala 25 18222 G2P1L1 08/01/15 15/10/15 12 WEEKS 2 DAYS 8.9 14.5 
70. mrs meenakshi 28 21333 G3P2L2 16/01/15 23/10/15 12 WEEKS 6 DAYS 7.6 16.6 
71. mrs mina 24 11231 G2P1L1 22/01/15 28/10/15 13 WEEKS 1 DAY 8.9 14.3 
72. mrs mekala 22 14311 G2P1L1 26/02/15 05/12/15 11 WEEKS 4 DAYS 8.7 10.1 
73. mrs ananditha 28 19881 G2P1L1 17/02/15 24/11/15 11 WEEKS 2 DAYS 6.9 14.5 
74. mrs kalaivani 30 20002 G2P1L1 21/03/15 28/12/15 10 WEEKS 1 DAY 9.3 15.3 
75. mrs preethi 23 23331 G2P1L1 03/01/15 10/10/15 13 WEEKS 3 DAYS 10.6 17.3 
76. mrs amritha 27 29911 G2P1L1 07/02/15 14/11/15 11 WEEKS 2 DAYS 12.3 18.5 
77. mrs ringu devi 22 27722 G2P1L1 28/01/15 05/11/15 12 WEEKS 5 DAYS 6.9 19.1 
78. mrs malliga 32 21122 G3P2L2 09/02/15 16/11/15  10 WEEKS 5 DAYS 7.8 10.1 
79.  mrs reena 35 14333 G2P1L1 15/01/15 22/10/15 13 WEEKS 2 DAYS 10.1 16.9 
80. mrs reeta devi 26 30011 G2P1L1 10/02/15 17/11/15 11 WEEKS 4 DAYS 4.3 19.3 
81. mrs dinakavi 28 27112 G2P1L1 05/03/15 12/12/15 12 WEEKS 5 DAYS 6.6 19.6 
82. mrs usha 26 28221 G2P1L1 12/12/14 19/09/15 13 WEEKS 2 DAYS 10.1 16.14 
83. mrs nirmala 22 22333 G2P1L1 27/12/14 03/09/15 10 WEEKS 4 DAYS 12.9 16.1 
84. mrs priyamani 29 21112 G2P1L1 01/12/14 08/09/15 10 WEEKS 2 DAYS 8.9 17.3 
85. mrs banu 25 18881 G2P1L1 08/12/14 15/09/15 11 WEEKS 5 DAYS 9.6 17.8 
86. mrs thulasi 32 21122 G2P1L1 10/01/15 17/10/15 10 WEEKS 6 DAYS 10.6 10.3 
87. mrs likitha 23 28877 G2P1L1 31/01/15 07/10/15 12 WEEKS 2 DAYS 12.9 11.2 
88. mrs sivalochini 26 27112 G2P1L1 28/02/15 07/11/15 13 WEEKS 12.3 13.3 
89. mrs preetha 20 30221 G3P2L2 04/04/15 11/01/16 13 WEEKS 1 DAY 10.2 14.5 
90. mrs sumathi 23 22233 G3P2L2 26/04/15 02/02/16 11 WEEKS 4 DAYS 7.3 16.7 
91. mrs devika 28 27711 G2P1L1 11/04/15 18/12/15 11 WEEKS 2 DAYS 9.8 19.8 
92. mrs sangeetha 23 28833 G2P1L1 28/03/15 04/12/15 10 WEEKS 1 DAY 14.1 10.8 
93. mrs amritha 21 29911 G2P1L1 16/03/15 23/12/15 13 WEEKS 3 DAYS 6.2 8.3 
94. mrs shobana 26 31122 G2P1L1 11/01/15 18/10/15 11 WEEKS 2 DAYS 7.8 19.3 
95. mrs sumathy 22 28221 G2P1L1 01/02/15 08/11/15 12 WEEKS 5 DAYS 10.1 15.2233 
96. mrs deepa 27 27112 G2P1L1 30/04/15 07/02/15 13 WEEKS 13.3 16.8 
97. mrs jayashree 33 22456 G2P1L1 02/02/15 09/11/15 12 WEEKS 3DAYS 8.3 18.3 
98. mrs ramya 26 11568 G2P1L1 01/04/15 08/01/16 10 WEEKS 4 DAYS 9.6 17.8 
99. mrs keerthi 27 19568 G2P1L1 02/12/15 09/09/16 12 WEEKS 3 DAYS 14.5 10.1 
100. Mrs. priya 22 25684  G2P1L1 23/09/15 30/06/16 11 WEEKS 2 DAYS 12.3 9.9 
``
 
ABBREVIATION 
RPL - Recurrent Pregnancy Loss 
HHCH - Hyperhomocysteinemia 
NTD - Neutral tube Defect 
RM - Recurrent Miscarriage 
PCOS - Polycystic Ovarian Syndrome 
A PAS - Antiphospholipid antibody syndrome 
MTHFR - Methylene tetrahydro folate Reductase 
LAC - Lupus Anticoagulant 
TLC - Tender Loving Care 
HCG - Human Chronic Gonadotrophin 
SD - Standard Deviation 
IUD - Intra Utrine Death 
TC - Transcobalamin 
 
 
 
 
 
 
 
 
 
  
PROFORMA 
NAME 
AGE 
IP/OP NO 
ADDRESS 
TELEPHONE NO 
MENSTURAL H/O 
• MENARCHY 
• CYCLES REGULAR/IRREGULAR 
• DURATION 
• LMP 
MARITAL H/O 
• AGE AT MARRIAGE 
• CONSAGNUITY 
OBSTETRIC H/O 
• YEARS AFTER MARRIAGE 
• NATURAL/ASSISTED 
• ANTENATAL PERIOD 
• 1ST TRIMESTER 
• 2ND TRIMESTER 
• 3RD TRIMESTER 
• PEDIGREE 
• PERI CONCEPTIONAL EXPOSURE 
• ILLNESS(FEVER,JAUNDICE) 
• MEDICATION 
• EXPOSURE 
FAMILY H/O 
• ABORTION,INFERTILITY,BIRTH 
• DEFECTS,MENTAL RETARDATION 
RESIDENCE H/O 
• (FACTORY,TANNERY,POLLUTED 
• WATER,RADIATION,BURNING) 
• OCCUPATION H/O 
GENERAL EXAMINATION 
• WIFE HUSBAND 
• VITALS 
• OBSTETRIC EXAMINATION 
60 
INVESTIGATIONS 
• Hb 
• BLOOD UREA 
• BLOOD SUGAR 
• SERUM CREATINE 
• HIV/VDRL 
• HbSAg 
• CERVICAL SWAB 
• HOMOCYSTEINE 
• USG 
• LFT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONSENT FORM 
I agree to participate in the study entitled “EVALUATION OF 
HOMOCYSTEINE & FOLIC ACID LEVELS IN PREGNANCY LOSS”. 
I confirm that I have been told about this study in my mother tongue and have had 
the opportunity to clarify my doubts. 
I understand that my participation  is voluntary and I may refuse to participate at any 
time without  giving any reasons and without affecting my benefits. 
I agree not to restrict the use  of any data or results that arise from this study. 
Name of the participant : 
Sign / Thumb print: 
Sign of Investigator : 
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